AI Science Tracker
EN

Incremental predictive value of CMR phenotyping for major adverse cardiovascular events: an interpretable machine learning study from UK Biobank

Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, China; Department of Cardiology, Meishan Branch of the Third Affiliated Hospital, Yan'an University School of Medicine, China · 31 Jul 2026 · medicine

Discovery

Incremental predictive value of CMR phenotyping for major adverse cardiovascular events: an interpretable machine learning study from UK Biobank

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: Unsupervised clustering and XGBoost with SHAP show CMR-derived phenotypes improve MACE prediction over conventional risk factors in UK Biobank, with an independent cross-modality cohort check.

Technology: Unsupervised clustering defines CMR phenotypes; XGBoost and SHAP assess their contribution to MACE-risk prediction.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Unsupervised clustering defines CMR phenotypes; XGBoost and SHAP assess their contribution to MACE-risk prediction.
Limitation / still unknown
notypes improve MACE prediction over conventional risk factors in UK Biobank, with an independent cross-modality cohort check.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1852547/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.